Executive summary of the KDIGO 2022 Clinical Practice Guideline for the prevention, diagnosis, evaluation, and treatment of hepatitis c in chronic kidney disease

Document Type

Article

Publication Date

12-1-2022

Abstract

Infection with the hepatitis C virus (HCV) has adverse liver, kidney, and cardiovascular consequences in patients with chronic kidney disease (CKD), including those on dialysis therapy or with a kidney transplant. Since the publication of the Kidney Disease: Improving Global Outcomes (KDIGO) HCV Guideline in 2018, advances in HCV management, particularly in the field of antiviral therapy and treatment of HCV-associated glomerular diseases, coupled with increased usage of HCV-positive kidney grafts, have prompted a reexamination of the 2018 guideline. As a result, the Work Group performed a comprehensive review and revised the 2018 guidance. This Executive Summary highlights key aspects of the updated guideline recommendations for 3 chapters: Chapter 2: Treatment of HCV infection in patients with CKD; Chapter 4: Management of HCV-infected patients before and after kidney transplantation; and Chapter 5: Diagnosis and management of kidney diseases associated with HCV infection.

Keywords

chronic kidney disease, cryoglobulinemia, dialysis, direct-acting antivirals, glomerular diseases, guideline, hemodialysis, hepatitis C virus, infection control, KDIGO, kidney transplantation, liver testing, nosocomial transmission, screening, systematic review

Publication Title

Kidney International

Divisions

medicinedept

Funders

KDIGO

Volume

102

Issue

6

Publisher

Elsevier Science Inc

Publisher Location

STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA

This document is currently not available here.

Share

COinS